Online inquiry

IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11307MR)

This product GTTS-WQ11307MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ITGAV&ITGB3 gene. The antibody can be applied in Sarcoma research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001144999.3; NM_000212.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3685; 3690
UniProt ID P06756; P05106
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGAV&ITGB3, MEDI-522(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ11307MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8709MR IVTScrip™ mRNA-Anti-F3, HuMax-TF-ADC(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HuMax-TF-ADC
GTTS-WQ7919MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GSK3196165
GTTS-WQ15524MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA UCB-7858
GTTS-WQ4793MR IVTScrip™ mRNA-Anti-DPP4, BT 5/9(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BT 5/9
GTTS-WQ13843MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-1193
GTTS-WQ13560MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PRX-302
GTTS-WQ15333MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ7174MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW